Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ERG activates a stem-like proliferation-differentiation program in prostate epithelial cells with mixed basal-luminal identity.
Feng W, Ladewig E, Salsabeel N, Zhao H, Lee YS, Gopalan A, Lange M, Luo H, Kang W, Fan N, Rosiek E, de Stanchina E, Chen Y, Carver BS, Leslie CS, Sawyers CL. Feng W, et al. Among authors: de stanchina e. bioRxiv [Preprint]. 2024 Apr 6:2023.05.15.540839. doi: 10.1101/2023.05.15.540839. bioRxiv. 2024. PMID: 38585869 Free PMC article. Preprint.
β4 Integrin signaling induces expansion of prostate tumor progenitors.
Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG. Yoshioka T, et al. Among authors: de stanchina e. J Clin Invest. 2013 Feb;123(2):682-99. doi: 10.1172/JCI60720. Epub 2013 Jan 25. J Clin Invest. 2013. PMID: 23348745 Free PMC article.
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.
Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N. Schwartz S, et al. Among authors: de stanchina e. Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24. Cancer Cell. 2015. PMID: 25544636 Free PMC article.
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Zhang Z, et al. Among authors: de stanchina e. Cancer Cell. 2020 Aug 10;38(2):279-296.e9. doi: 10.1016/j.ccell.2020.06.005. Epub 2020 Jul 16. Cancer Cell. 2020. PMID: 32679108 Free PMC article.
Rapid interrogation of cancer cell of origin through CRISPR editing.
Feng W, Cao Z, Lim PX, Zhao H, Luo H, Mao N, Lee YS, Rivera AA, Choi D, Wu C, Han T, Romero R, de Stanchina E, Carver BS, Wang Q, Jasin M, Sawyers CL. Feng W, et al. Among authors: de stanchina e. Proc Natl Acad Sci U S A. 2021 Aug 10;118(32):e2110344118. doi: 10.1073/pnas.2110344118. Proc Natl Acad Sci U S A. 2021. PMID: 34353917 Free PMC article.
ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. Clegg NJ, et al. Among authors: de stanchina e. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. Cancer Res. 2012. PMID: 22266222 Free PMC article.
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL. Mu P, et al. Among authors: de stanchina e. Science. 2017 Jan 6;355(6320):84-88. doi: 10.1126/science.aah4307. Science. 2017. PMID: 28059768 Free PMC article.
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. Zhang Z, et al. Among authors: de stanchina e. Cancer Cell. 2020 Apr 13;37(4):584-598.e11. doi: 10.1016/j.ccell.2020.03.001. Epub 2020 Mar 26. Cancer Cell. 2020. PMID: 32220301 Free PMC article.
245 results